IFresh And CytRx Corporation Among The List Of The Most Active Winners And Losers Of Tuesday’s US Session
IFresh And CytRx Corporation Among The List Of The Most Active Winners And Losers Of Tuesday’s US Session
(VIANEWS) – Another day of trading has ended and here's today's list of stocks that have had significant trading activity in the US session.
(VIANEWS)-又一個交易日結束了,以下是今天在美國交易時段有重大交易活動的股票名單。
The three most active and biggest winners today are iFresh, Super Micro Computer, and CYREN Ltd..
今天最活躍和最大的三個贏家是iFresh、超級微型計算機和CYREN有限公司。
Rank | Financial Asset | Price | Change | Updated (EST) |
---|---|---|---|---|
1 | iFresh (IFMK) | 0.05 | 719.67% | 2022-04-19 14:19:44 |
2 | Super Micro Computer (SMCI) | 44.55 | 21.69% | 2022-04-19 14:47:33 |
3 | CYREN Ltd. (CYRN) | 2.71 | 12.92% | 2022-04-18 19:06:06 |
4 | Escalon Medical Corp. (ESMC) | 0.11 | 10% | 2022-04-19 04:17:06 |
5 | Plug Power (PLUG) | 28.07 | 9.84% | 2022-04-19 14:59:16 |
6 | Roku (ROKU) | 117.01 | 8.44% | 2022-04-19 14:51:50 |
7 | Celsius Holdings (CELH) | 57.20 | 7.82% | 2022-04-19 14:49:49 |
8 | GameStop (GME) | 152.27 | 7.64% | 2022-04-19 14:58:38 |
9 | StoneCo (STNE) | 11.10 | 7.45% | 2022-04-19 14:52:04 |
10 | Generac Holdlings (GNRC) | 267.46 | 7.3% | 2022-04-19 14:57:02 |
職級 | 金融資產 | 價格 | 變化 | 更新(美國東部夏令時) |
---|---|---|---|---|
1 | IFresh(IFMK) | 0.05 | 719.67% | 2022-04-19 14:19:44 |
2 | 超級微型計算機(SMCI) | 44.55 | 21.69% | 2022-04-19 14:47:33 |
3 | 賽瑞恩有限公司(Cyren Ltd.) | 2.71 | 12.92% | 2022-04-18 19:06:06 |
4 | 埃斯卡隆醫療公司(Escalon Medical Corp.) | 0.11 | 10% | 2022-04-19 04:17:06 |
5 | 插頭電源(插頭) | 28.07 | 9.84% | 2022-04-19 14:59:16 |
6 | 羅庫(Roku) | 117.01 | 8.44% | 2022-04-19 14:51:50 |
7 | 攝氏控股(Celsius Holdings) | 57.20 | 7.82% | 2022-04-19 14:49:49 |
8 | 遊戲停止(GME) | 152.27 | 7.64% | 2022-04-19 14:58:38 |
9 | StoneCo(STNE) | 11.10 | 7.45% | 2022-04-19 14:52:04 |
10 | 通用控股公司(GNRC) | 267.46 | 7.3% | 2022-04-19 14:57:02 |
The three most active and biggest losers today are CytRx Corporation, Esperion Therapeutics, and Evolving Systems.
今天最活躍和最大的三家輸家是CytRx公司、Esperion治療公司和演進系統公司。
Rank | Financial Asset | Price | Change | Updated (EST) |
---|---|---|---|---|
1 | CytRx Corporation (CYTR) | 0.13 | -28.89% | 2022-04-18 19:08:06 |
2 | Esperion Therapeutics (ESPR) | 5.03 | -14.6% | 2022-04-19 04:23:18 |
3 | Evolving Systems (EVOL) | 1.28 | -11.72% | 2022-04-19 05:07:12 |
4 | FalconStor Software (FALC) | 1.04 | -9.57% | 2022-04-19 05:23:15 |
5 | DURECT Corporation (DRRX) | 0.44 | -7.64% | 2022-04-18 21:14:06 |
6 | First Majestic Silver (AG) | 13.00 | -6.41% | 2022-04-19 14:55:47 |
7 | Fate Therapeutics (FATE) | 35.48 | -6.06% | 2022-04-19 07:07:07 |
8 | Epizyme (EPZM) | 0.72 | -6.03% | 2022-04-19 03:13:13 |
9 | TherapeuticsMD (TXMD) | 0.27 | -5.74% | 2022-04-19 14:52:30 |
10 | Enanta Pharmaceuticals (ENTA) | 70.50 | -5.05% | 2022-04-19 03:09:07 |
職級 | 金融資產 | 價格 | 變化 | 更新(美國東部夏令時) |
---|---|---|---|---|
1 | CytRx公司(CytRx Corporation) | 0.13 | -28.89% | 2022-04-18 19:08:06 |
2 | Esperion Treateutics(ESPR) | 5.03 | -14.6% | 2022-04-19 04:23:18 |
3 | 發展中的系統(EVOL) | 1.28 | -11.72% | 2022-04-19 05:07:12 |
4 | FalconStor軟件(Falc) | 1.04 | -9.57% | 2022-04-19 05:23:15 |
5 | DURECT公司(DURECT Corporation) | 0.44 | -7.64% | 2022-04-18 21:14:06 |
6 | 第一枚Majestic銀牌(AG) | 13.00 | -6.41% | 2022-04-19 14:55:47 |
7 | 命運治療(Fate Treateutics) | 35.48 | -6.06% | 2022-04-19 07:07:07 |
8 | EPizyme(EPZM) | 0.72 | -6.03% | 2022-04-19 03:13:13 |
9 | 治療藥物(TXMD) | 0.27 | -5.74% | 2022-04-19 14:52:30 |
10 | 埃南塔製藥公司(Enta) | 70.50 | -5.05% | 2022-04-19 03:09:07 |
Most Active Winners today
今天最活躍的獲獎者
1. iFresh (IFMK) – 719.67%
1.iFresh(IFMK)-719.67%
Through its subsidiaries, iFresh Inc. operates a network grocery store chains in the northern-eastern United States. The company operates in two segments: Wholesale and Retail. It offers vegetables, seafood and meats as well as snacks and seasonings. The company's brands include Feiyan and Green Acre as well as Redolent, Redolent and Golden Smell. It also sells products in wholesale shops, supermarkets and restaurants. It had nine supermarkets, two wholesale shops and one in-house business. It sells its products online and has a delivery network throughout suburban areas. Founded in 1995, iFresh Inc. is based in Long Island City (New York).
通過其子公司,iFresh Inc.在美國東北部經營着一個雜貨連鎖店網絡。該公司在兩個領域開展業務:批發和零售。它提供蔬菜、海鮮和肉類,以及小吃和調味品。該公司的品牌包括飛燕和綠茵以及回味劑、回味劑和金色氣味。它還在批發店、超市和餐館銷售產品。它有九家超市,兩家批發店和一家內部企業。它在網上銷售產品,並在整個郊區建立了送貨網絡。IFresh Inc.成立於1995年,總部設在紐約長島市。
NASDAQ ended the session with iFresh rising 719.67% to $0.05 on Tuesday while NASDAQ jumped 2.15% to $13,619.66.
週二,納斯達克收盤時iFresh上漲719.67%,至每股0.05美元,納斯達克上漲2.15%,至每股13,619.66美元。
Volume
卷
Today's last reported volume for iFresh is 9902 which is 125.14% above its average volume of 4398.
今天iFresh最新公佈的成交量為9,902台,比4,398台的平均成交量高出125.14%。
iFresh's last close was $0.01, 99.64% under its 52-week high of $1.68.
IFresh最新收盤報0.01美元,較1.68美元的52周高點低99.64%。
iFresh's Revenue
IFresh的收入
Year-on-year quarterly revenue growth grew by 22.7%, now sitting on 94.26M for the twelve trailing months.
季度營收同比增長22.7%,連續12個月增長9426萬。
Stock Price Classification
股票價格分類
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,
根據隨機振盪器,一個有用的超買和超賣狀態指標,
iFresh's stock is considered to be oversold (<=20).
IFresh的股票被認為是超賣(
iFresh's Stock Yearly Top and Bottom Value
IFresh的年度庫存最高和最低值
iFresh's stock is valued at $0.05 at 17:32 EST, way below its 52-week high of $1.68 and way higher than its 52-week low of $0.00.
美國東部時間17:32,iFresh的股價為0.05美元,遠低於1.68美元的52周高點,遠高於0.00美元的52周低點。
iFresh's Moving Average
IFresh移動平均線
iFresh's worth is way above its 50-day moving average of $0.02 and way below its 200-day moving average of $0.60.
IFresh的價值遠高於50日移動均線0.02美元,遠低於200日移動均線0.60美元。
More news about iFresh.
更多關於iFresh的新聞。
2. Super Micro Computer (SMCI) – 21.69%
2.超級微型計算機(SMCI)-21.69%
Super Micro Computer, Inc., along with its affiliates, designs and produces high-performance storage and server solutions that are modular and open-architecture. The company's products include complete servers and storage as well as modular blade servers and blades. It also offers full racks and networking devices as well as server management software and sub-systems. Support and services are provided by the subsidiaries. The company also provides a range of application-optimized server solutions, including rackmount and blade servers, storage systems, and subsystems and accessories; and server software management solutions, such as Server Management Suite, including Supermicro Server Manager, Supermicro Power Management software, Supermicro Update Manager, and SuperDoctor 5. It also offers accessories and subsystems for server boards and chassis. The company also offers server system configuration and upgrade services. It also provides technical documentation. It also offers on-site and help desk support for server and storage system; as well as customer support, which includes ongoing maintenance and technical support. It sells its products to enterprises, cloud computing and artificial intelligence markets, as well as 5G and edge computing market. The company sells products via direct sales, distributors and value-added resellers. It operates primarily in America, Europe, Asia and abroad. Super Micro Computer, Inc., was established in 1993. Its headquarters are in San Jose, California.
超級微型計算機公司及其附屬公司設計和生產模塊化和開放式架構的高性能存儲和服務器解決方案。該公司的產品包括完整的服務器和存儲以及模塊化刀片服務器和刀片。它還提供完整的機架和網絡設備以及服務器管理軟件和子系統。支持和服務由子公司提供。該公司還提供一系列應用優化的服務器解決方案,包括機架式和刀片式服務器、存儲系統以及子系統和附件;以及服務器軟件管理解決方案,例如服務器管理套件,包括SuperMicro服務器管理器、SuperMicro電源管理軟件、SuperMicro更新管理器和SuperDoctor 5。該公司還提供服務器主板和機箱的附件和子系統。該公司還提供服務器系統配置和升級服務。它還提供了技術文檔。它還為服務器和存儲系統提供現場和幫助台支持;以及客户支持,包括持續維護和技術支持。它向企業、雲計算和人工智能市場以及5G和邊緣計算市場銷售產品。該公司通過直銷、分銷商和增值經銷商銷售產品。它主要在美國、歐洲、亞洲和海外運營。超微計算機有限公司成立於1993年。它的總部設在加利福尼亞州的聖何塞。
NASDAQ ended the session with Super Micro Computer rising 21.69% to $44.55 on Tuesday, after five consecutive sessions in a row of gains. NASDAQ jumped 2.15% to $13,619.66, after two sequential sessions in a row of losses, on what was an all-around bullish trend exchanging session today.
週二,納斯達克在連續五個交易日上漲後,收盤上漲21.69%,至每股44.55美元。納斯達克在連續兩個交易日下跌後躍升2.15%,至13,619.66美元,今日是全面看漲的趨勢交流會。
Volume
卷
Today's last reported volume for Super Micro Computer is 1454280 which is 500.34% above its average volume of 242242.
今天最新公佈的超微計算機成交量為1454280台,比242242台的平均成交量高出500.34%。
Super Micro Computer's last close was $36.61, 23.71% under its 52-week high of $47.99.
Super Micro Computer收盤報36.61美元,較其52周高點47.99美元低23.71%。
The company's growth estimates for the current quarter and the next is 23.8% and 50%, respectively.
該公司對當前季度和下一季度的增長預估分別為23.8%和50%。
Super Micro Computer's Revenue
超級微型計算機的收入
Year-on-year quarterly revenue growth grew by 35.5%, now sitting on 3.83B for the twelve trailing months.
與去年同期相比,季度收入增長了35.5%,連續12個月增長38.3億。
Stock Price Classification
股票價格分類
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,
根據隨機振盪器,一個有用的超買和超賣狀態指標,
Super Micro Computer's stock is considered to be oversold (<=20).
超微電腦(Super Micro Computer)的股票被認為超賣(
Super Micro Computer's Stock Yearly Top and Bottom Value
超微計算機的股票年度最高和最低值
Super Micro Computer's stock is valued at $44.55 at 17:32 EST, below its 52-week high of $47.99 and way above its 52-week low of $32.88.
美國東部時間17:32,超微電腦的股價為44.55美元,低於其52周高點47.99美元,遠高於其52周低點32.88美元。
Super Micro Computer's Moving Average
超級微型計算機的移動平均
Super Micro Computer's value is way higher than its 50-day moving average of $40.04 and way above its 200-day moving average of $39.21.
超級微型計算機的價值遠高於其50日移動均線切入位40.04美元,也遠高於其200日移動均線切入位39.21美元。
More news about Super Micro Computer.
更多關於超級微型計算機的新聞。
3. CYREN Ltd. (CYRN) – 12.92%
3.Cyren Ltd.(CyRN)-12.92%
Cyren Ltd. and its subsidiaries develop and market information security solutions to protect Web, email and mobile transactions across the United States, Germany and other European countries. They also sell these products internationally. It offers software-as-a-service (SaaS) cybersecurity solutions that protect businesses, their employees, and customers from email, files, and the web threats. Cyren offers threat detection services. These include an email security engine with anti-spam outbound, IP reputation and virus outbreak detection; a malware detection engine to protect email apps; and a Web security engine to help customers provide URL classification to allow web browser filtering. Cyren also offers threat intelligence products such as real-time threat detection, threat hunting and threat hunting intelligence. Cyren Enterprise Email Security products are also offered by the company, such as Cyren Email Security (a cloud-based secure mail gateway), Cyren Inbox Security (an anti-phishing product for Microsoft 365) and Cyren Threat InDepth. This threat intelligence allows executives and security personnel to see evolving threats to their email systems and makes decisions about how to minimize them. The company sells products via direct and indirect channels. These include distributors and value-added resellers. It also offers managed services to enterprises and original equipment producers. The former name of the company was Commtouch Software Ltd., but it changed its name in January 2014 to Cyren Ltd. Cyren Ltd. was founded in 1991. It is located in Herzliya in Israel.
CyREN有限公司及其子公司開發和營銷信息安全解決方案,以保護美國、德國和其他歐洲國家的網絡、電子郵件和移動交易。他們還在國際上銷售這些產品。它提供軟件即服務(SaaS)網絡安全解決方案,保護企業、員工和客户免受電子郵件、文件和網絡威脅。CyREN提供威脅檢測服務。其中包括具有反垃圾郵件出站、IP聲譽和病毒爆發檢測的電子郵件安全引擎;保護電子郵件應用程序的惡意軟件檢測引擎;以及幫助客户提供URL分類以允許網絡瀏覽器過濾的網絡安全引擎。CyREN還提供威脅情報產品,如實時威脅檢測、威脅追捕和威脅追捕情報。該公司還提供Cyren企業電子郵件安全產品,如Cyren電子郵件安全(基於雲的安全郵件網關)、Cyren收件箱安全(Microsoft 365的反釣魚產品)和Cyren Threat深度。這種威脅情報使高管和安全人員能夠看到他們的電子郵件系統面臨的不斷變化的威脅,並就如何將威脅降至最低做出決定。該公司通過直接和間接渠道銷售產品。其中包括分銷商和增值經銷商。它還為企業和原始設備生產商提供託管服務。該公司的前身是Commouch Software Ltd.,但在2014年1月更名為Cyren Ltd.。Cyren Ltd.成立於1991年。它位於以色列的赫茲利亞。
NASDAQ ended the session with CYREN Ltd. jumping 12.92% to $2.71 on Tuesday while NASDAQ jumped 2.15% to $13,619.66.
納斯達克週二收盤上漲12.92%,至2.71美元,納斯達克上漲2.15%,至13,619.66美元。
Volume
卷
Today's last reported volume for CYREN Ltd. is 3499560 which is 13.96% below its average volume of 4067550.
今日公佈的最新成交量為3499560只,較4067550只的平均成交量低13.96%。
CYREN Ltd.'s last close was $2.71, 85.74% below its 52-week high of $19.00.
Cyren Ltd.收盤報2.71美元,較19.00美元的52周高點低85.74%。
CYREN Ltd.'s Revenue
Cyren Ltd.的收入
Year-on-year quarterly revenue growth declined by 12.8%, now sitting on 31.19M for the twelve trailing months.
季度營收同比增長12.8%,連續12個月保持在3119萬美元。
Stock Price Classification
股票價格分類
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,
根據隨機振盪器,一個有用的超買和超賣狀態指標,
CYREN Ltd.'s stock is considered to be oversold (<=20).
Cyren Ltd.的股票被認為是超賣的(
CYREN Ltd.'s Stock Yearly Top and Bottom Value
賽倫股份有限公司股票年度最高和最低價值
CYREN Ltd.'s stock is valued at $2.71 at 17:32 EST, way below its 52-week high of $19.00 and way higher than its 52-week low of $1.98.
截至美國東部時間17點32分,Cyren Ltd.的股價為2.71美元,遠低於19.00美元的52周高點,遠高於1.98美元的52周低點。
CYREN Ltd.'s Moving Average
Cyren Ltd.的移動平均線
CYREN Ltd.'s worth is way under its 50-day moving average of $4.91 and way under its 200-day moving average of $8.32.
該公司的市值遠低於50日移動均線切入位4.91美元,也遠低於200日移動均線切入位8.32美元。
More news about CYREN Ltd..
更多關於CYREN有限公司的新聞。
4. Escalon Medical Corp. (ESMC) – 10%
4.Escalon Medical Corp.(ESMC)-10%
Escalon Medical Corp. designs, produces, markets and distributes pharmaceuticals and medical devices in the field of ophthalmology both in the United States as well internationally. A-Scan provides details about the inner structure of your eye. B-Scan is a diagnostic tool which gives information to doctors if the media inside the eye become opaque or cloudy. UBM provides high-frequency/high-resolution ultrasound information that provides precise information about the anterior section of your eye. Pachymeter measures the cornea's thickness. It also sells intraocular gases products such as SF6 and C3F8 that are used in vitreoretinal surgery as a temporary tamponade during detached retina surgery. The company manufactures and distributes a patented universal gas delivery kit, which delivers gas directly from the canister. It also offers disposable surgical bags that can be used for vitreoretinal surgeries; as well as AXIS Image Management System, which allows you to manage images via the Web browser using any device, regardless of manufacturer or modality. Independent sales reps and a network distributors sell the company's products to hospitals. Internal sales staff also help with sales. Escalon Medical Corp. is located in Wayne, Pennsylvania.
Escalon醫療公司在美國和國際上設計、生產、營銷和分銷眼科領域的藥品和醫療器械。A-Scan提供了有關眼睛內部結構的詳細信息。B超是一種診斷工具,如果眼睛內的介質變得不透明或渾濁,它會向醫生提供信息。UBM提供高頻/高分辨率超聲信息,提供有關眼睛前部的準確信息。厚度計測量角膜的厚度。它還銷售眼內氣體產品,如SF6和C3F8,用於玻璃體視網膜手術,作為視網膜脱離手術期間的臨時填充物。該公司製造和分銷一種獲得專利的通用氣體輸送套件,該套件直接從毒氣罐輸送氣體。它還提供可用於玻璃體視網膜手術的一次性手術袋;以及AXIS圖像管理系統,該系統允許您使用任何設備通過Web瀏覽器管理圖像,而無論製造商或設備。獨立的銷售代表和網絡分銷商向醫院銷售該公司的產品。內部銷售人員也會幫助銷售。Escalon醫療公司位於賓夕法尼亞州韋恩市。
NASDAQ ended the session with Escalon Medical Corp. rising 10% to $0.11 on Tuesday, after two successive sessions in a row of gains. NASDAQ jumped 2.15% to $13,619.66, after two consecutive sessions in a row of losses, on what was an all-around positive trend exchanging session today.
納斯達克週二收盤上漲10%,至0.11美元,此前連續兩個交易日上漲。納斯達克在連續兩個交易日下跌後躍升2.15%,至13619.66美元,今日是全面上漲的趨勢交流時段。
Volume
卷
Today's last reported volume for Escalon Medical Corp. is 11267 which is 10.6% below its average volume of 12603.
今日Escalon Medical Corp.最新公佈的成交量為11267只,較12603只的平均成交量低10.6%。
Escalon Medical Corp.'s last close was $0.11, 75% below its 52-week high of $0.44.
Escalon Medical Corp.收盤報0.11美元,較0.44美元的52周高點低75%。
Escalon Medical Corp.'s Revenue
Escalon醫療公司的收入
Year-on-year quarterly revenue growth declined by 6.8%, now sitting on 10.54M for the twelve trailing months.
季度營收同比增長6.8%,連續12個月保持在1054萬美元的水平。
Escalon Medical Corp.'s Stock Yearly Top and Bottom Value
Escalon醫療公司股票年度最高和最低價值
Escalon Medical Corp.'s stock is valued at $0.11 at 17:32 EST, way under its 52-week high of $0.44 and way higher than its 52-week low of $0.08.
美國東部時間17點32分,Escalon Medical Corp.的股價為0.11美元,遠低於0.44美元的52周高點,也遠高於0.08美元的52周低點。
Escalon Medical Corp.'s Moving Average
埃斯卡隆醫療公司的移動平均線
Escalon Medical Corp.'s worth is below its 50-day moving average of $0.11 and way under its 200-day moving average of $0.15.
Escalon Medical Corp.的市值低於50日移動均線0.11美元,也遠低於200日移動均線0.15美元。
More news about Escalon Medical Corp..
更多關於Escalon醫療公司的新聞。
5. Plug Power (PLUG) – 9.84%
5.插頭功率(Plug)-9.84%
Plug Power Inc. offers turnkey hydrogen fuel cell solutions to the stationary and electric mobility markets of North America and Europe. The company specializes in proton exchange membrane fuel cells and fuel processing technologies. It also offers fuel cell/battery hybrid technology and hydrogen storage and dispensing infrastructure. GenDrive is a hydrogen-fueled, PEM fuelcell system for electric vehicle material handling; GenFuel provides hydrogen fueling generation, storage and dispensing systems; GenCare provides ongoing support and maintenance programs for GenDrive fuel cells and GenSure products; GenSure provides stationary fuel cell solutions that provide modular PEM fuel cell power that can be used to meet the grid-support and backup power needs of the utility, transportation and telecommunication sectors. GenKey is a complete solution to transition to fuel cell power. ProGen is a fuel stack and engine technology that can be used in stationary and mobile fuel cells systems as well as in electric delivery vans. It sells its products through direct sales, OEM manufacturers and dealer networks. Plug Power Inc. was established in 1997 in Latham (New York).
Plug Power Inc.為北美和歐洲的固定和電動移動市場提供全包式氫燃料電池解決方案。該公司專門從事質子交換膜燃料電池和燃料加工技術。它還提供燃料電池/電池混合技術以及氫存儲和分配基礎設施。GenDrive是一款氫燃料PEM燃料電池系統,用於電動汽車材料處理;GenFuel提供氫燃料發電、儲存和分配系統;GenCare為GenDrive燃料電池和GenSure產品提供持續支持和維護計劃;GenSure提供固定式燃料電池解決方案,提供模塊化PEM燃料電池電源,可用於滿足公用事業、交通和電信部門的電網支持和備用電源需求。GenKey是過渡到燃料電池動力的完整解決方案。Progen是一種可用於固定和移動燃料電池系統以及電動送貨車的燃料堆和發動機技術。它通過直銷、OEM製造商和經銷商網絡銷售產品。Plug Power Inc.於1997年在紐約萊瑟姆成立。
NASDAQ ended the session with Plug Power jumping 9.84% to $28.07 on Tuesday while NASDAQ rose 2.15% to $13,619.66.
納斯達克週二收盤時上漲9.84%,至28.07美元,納斯達克上漲2.15%,至13,619.66美元。
Volume
卷
Today's last reported volume for Plug Power is 42288100 which is 100.03% above its average volume of 21140800.
今天,Plug Power的最新成交量為42288100台,比21140800台的平均成交量高出100.03%。
Plug Power's last close was $25.55, 45.05% below its 52-week high of $46.50.
Plug Power最新收盤報25.55美元,較52周高位46.50美元低45.05%。
News about Plug Power today
今天關於Plug Power的新聞
- Plug Power stock surges after liquid green hydrogen delivery agreement with Walmart. According to today's article on MarketWatch, "Shares of Plug Power Inc. surged 4.4% in premarket trading Tuesday, after the alternative energy company disclosed an agreement with Walmart Inc. for an option to deliver up to 20 tons per day of liquid green hydrogen. ", "Walmart has been an early adopter of innovative hydrogen and fuel cell technology for over a decade, and our hydrogen-powered solutions offer a tool to enhance productivity improvements for Walmart's operations," said Plug Power Chief Executive Andy Marsh. "
- Plug Power shares rise after inking hydrogen delivery deal with Walmart. According to today's article on MarketWatch, "Shares of Plug Power Inc. surged 4.4% in premarket trading Tuesday, after the alternative energy company disclosed an agreement with Walmart Inc. for an option to deliver up to 20 tons per day of liquid green hydrogen. ", "Walmart has been an early adopter of innovative hydrogen and fuel cell technology for over a decade, and our hydrogen-powered solutions offer a tool to enhance productivity improvements for Walmart's operations," said Plug Power Chief Executive Andy Marsh. "
- 在與沃爾瑪達成液體綠色氫氣交付協議後,Plug Power股價飆升。根據MarketWatch上今天的文章,Plug Power Inc.的股價週二盤前交易中飆升4.4%,此前這家替代能源公司披露了與沃爾瑪(Walmart Inc.)達成的一項協議,每天最多交付20噸液態綠色氫氣。Plug Power首席執行長馬什(Andy Marsh)説,十多年來,沃爾瑪一直是創新氫和燃料電池技術的早期採用者,我們的氫動力解決方案為沃爾瑪的運營提供了一種提高生產率的工具。“
- Plug Power股價在與沃爾瑪簽署氫氣交付協議後上漲。根據MarketWatch上今天的文章,Plug Power Inc.的股價週二盤前交易中飆升4.4%,此前這家替代能源公司披露了與沃爾瑪(Walmart Inc.)達成的一項協議,每天最多交付20噸液態綠色氫氣。Plug Power首席執行長馬什(Andy Marsh)説,十多年來,沃爾瑪一直是創新氫和燃料電池技術的早期採用者,我們的氫動力解決方案為沃爾瑪的運營提供了一種提高生產率的工具。“
Plug Power's Sales
Plug Power的銷售額
Plug Power's sales growth is 65% for the present quarter and 108.4% for the next. The company's growth estimates for the current quarter and the next is 91.1% and 25%, respectively.
Plug Power本季度的銷售額增長率為65%,下一季度為108.4%。該公司對當前季度和下一季度的增長預估分別為91.1%和25%。
Plug Power's Revenue
Plug Power的收入
Year-on-year quarterly revenue growth grew by 34.4%, now sitting on 31.34M for the twelve trailing months.
季度營收同比增長34.4%,連續12個月增長3134萬。
Stock Price Classification
股票價格分類
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,
根據隨機振盪器,一個有用的超買和超賣狀態指標,
Plug Power's stock is considered to be overbought (>=80).
Plug Power的股票被認為是超買(>=80)。
Plug Power's Stock Yearly Top and Bottom Value
Plug Power的股票年度最高和最低值
Plug Power's stock is valued at $28.07 at 17:32 EST, way under its 52-week high of $46.50 and way above its 52-week low of $17.51.
在美國東部時間17:32,Plug Power的股價為28.07美元,遠低於46.50美元的52周高點,也遠高於17.51美元的52周低點。
Plug Power's Moving Average
Plug Power移動平均線
Plug Power's value is way higher than its 50-day moving average of $24.60 and under its 200-day moving average of $28.57.
Plug Power的價值遠高於其50日移動均線24.60美元,低於其200日移動均線28.57美元。
More news about Plug Power.
更多關於Plug Power的新聞。
6. Roku (ROKU) – 8.44%
6.Roku(Roku)-8.44%
Roku, Inc., along with its affiliates, operate a streaming TV platform. It operates under two distinct segments: Platform and Player. The company's platform allows people to search for and find different TV shows and movies, live music and news. The company has 36.9million active accounts as of December 31, 2019. The company also offers advertising products such as videos ads, brand sponsorships and audience development campaigns. It manufactures and licenses TVs and subscription billing services. The company also offers accessories and streaming media players under the Roku name. It sells brand-name channel buttons for remote controls. The company sells its products through distributors and retailers as well as direct to its customers via its website. It has offices in several countries, including the United States, Canada and Mexico. It was established in Los Gatos in California in 2002.
Roku,Inc.及其附屬公司運營着一個流媒體電視平臺。它分為兩個不同的部分:平臺和玩家。該公司的平臺允許人們搜索和找到不同的電視節目和電影、現場音樂和新聞。截至2019年12月31日,該公司擁有3690萬活躍賬户。該公司還提供美國存托股份視頻、品牌贊助和受眾發展活動等廣告產品。它製造和授權電視和訂閲計費服務。該公司還以Roku的名義提供配件和流媒體播放器。它銷售用於遙控器的品牌頻道按鈕。該公司通過分銷商和零售商銷售其產品,並通過其網站直接向客户銷售。它在包括美國、加拿大和墨西哥在內的幾個國家設有辦事處。它於2002年在加利福尼亞州的洛斯加託斯成立。
NASDAQ ended the session with Roku jumping 8.44% to $117.01 on Tuesday, after five sequential sessions in a row of losses. NASDAQ rose 2.15% to $13,619.66, after two successive sessions in a row of losses, on what was an all-around positive trend trading session today.
週二,在連續五個交易日下跌後,納斯達克收盤大漲8.44%,至117.01美元。納斯達克在連續兩個交易日下跌後上漲2.15%,至13,619.66美元,今日是全面上漲的趨勢交易日。
Volume
卷
Today's last reported volume for Roku is 5732150 which is 22.99% below its average volume of 7443500.
今天,Roku的最新報告成交量為5732150台,比其平均成交量7443500台低22.99%。
Roku's last close was $107.91, 78.01% below its 52-week high of $490.76.
Roku最新收盤報107.91美元,較52周高點490.76美元低78.01%.
Roku's Sales
Roku的銷售額
Roku's sales growth is 84.7% for the current quarter and 46.7% for the next. The company's growth estimates for the current quarter and the next is a negative 33.3% and a negative 61.2%, respectively.
Roku本季度的銷售額增長為84.7%,下一季度為46.7%。該公司對當前季度和下一季度的增長預期分別為負33.3%和負61.2%。
Roku's Revenue
Roku的收入
Year-on-year quarterly revenue growth grew by 79%, now sitting on 2.03B for the twelve trailing months.
與去年同期相比,季度收入增長了79%,連續12個月增長20.3億。
Stock Price Classification
股票價格分類
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,
根據隨機振盪器,一個有用的超買和超賣狀態指標,
Roku's stock is considered to be overbought (>=80).
Roku的股票被認為是超買(>=80)。
Roku's Stock Yearly Top and Bottom Value
Roku的股票年度最高和最低價值
Roku's stock is valued at $117.01 at 17:32 EST, way below its 52-week low of $196.94.
美國東部時間17:32,Roku的股票估值為117.01美元,遠低於52周低點196.94美元。
Roku's Moving Average
羅庫移動平均線
Roku's worth is way under its 50-day moving average of $280.17 and way below its 200-day moving average of $341.49.
Roku的市值遠低於50日移動均線切入位280.17美元,也遠低於200日移動均線切入位341.49美元。
More news about Roku.
更多關於Roku的新聞。
7. Celsius Holdings (CELH) – 7.82%
7.Celsius Holdings(CELH)-7.82%
Celsius Holdings, Inc. markets, distributes, sells and promotes functional, calorie-burning, fitness drinks in the United States as well as internationally. It offers a variety of beverages, such as carbonated orange and wild berry, cola and grape, kiwi guava and watermelon. Celsius Heat is a nutritional supplement that contains carbonated flavorings such as orange jack'd and blueberry pomegranate. Blueberry pomegranate. strawberry dragonfruit. tangerine grapefruit. It distributes products via direct-store distribution distributors as well as retailers that include supermarkets and convenience stores as well as drug and nutritional stores and mass merchants. In January 2007, Celsius Holdings, Inc. was established. Celsius Holdings, Inc., was established in 2004. It is located in Boca Raton, Florida.
Celsius Holdings,Inc.在美國和國際上營銷、分銷、銷售和推廣功能性、燃燒卡路里的健身飲料。它提供各種飲料,如碳酸橙子和野莓,可樂和葡萄,獼猴桃番石榴和西瓜。攝氏熱量是一種營養補充劑,含有碳酸調味品,如橙子傑克和藍莓石榴。藍莓石榴。草莓火龍果。橘子葡萄柚。它通過直營店分銷分銷商以及零售商(包括超市和便利店以及藥品和營養品商店和大眾商家)分銷產品。2007年1月,Celsius Holdings,Inc.成立。Celsius Holdings,Inc.成立於2004年。它位於佛羅裏達州博卡拉頓。
NASDAQ ended the session with Celsius Holdings jumping 7.82% to $57.20 on Tuesday, after two successive sessions in a row of losses. NASDAQ rose 2.15% to $13,619.66, after two successive sessions in a row of losses, on what was an all-around up trend trading session today.
納斯達克在連續兩個交易日下跌後,週二收盤上漲7.82%,至每股57.2美元。納斯達克在連續兩個交易日下跌後上漲2.15%,至13,619.66美元,今日是一個全面上漲的交易日。
Volume
卷
Today's last reported volume for Celsius Holdings is 545244 which is 42.07% below its average volume of 941345.
今天,Celsius Holdings最新公佈的成交量為545244只,比其平均成交量941345只低了42.07%。
Celsius Holdings's last close was $53.05, 51.87% below its 52-week high of $110.22.
Celsius Holdings最新收盤報53.05美元,較52周高點110.22美元低51.87%.
Celsius Holdings's Sales
Celsius Holdings的銷售額
Celsius Holdings's sales growth is 151.4% for the ongoing quarter and 108.3% for the next. The company's growth estimates for the present quarter and the next is 100% and 400%, respectively.
Celsius Holdings的銷售額在本季度的增長率為151.4%,下一季度為108.3%。該公司對當前季度和下一季度的增長預估分別為100%和400%。
Celsius Holdings's Revenue
Celsius Holdings的收入
Year-on-year quarterly revenue growth grew by 157.6%, now sitting on 245.68M for the twelve trailing months.
季度營收同比增長157.6%,連續12個月達到2.4568億歐元。
Celsius Holdings's Stock Yearly Top and Bottom Value
Celsius Holdings的股票年度最高和最低價值
Celsius Holdings's stock is valued at $57.20 at 17:32 EST, way below its 52-week high of $110.22 and way above its 52-week low of $39.45.
在美國東部時間17點32分,Celsius Holdings的股價為57.2美元,遠低於52周高點110.22美元,遠高於52周低點39.45美元。
Celsius Holdings's Moving Average
Celsius Holdings的移動平均線
Celsius Holdings's worth is above its 50-day moving average of $54.72 and way under its 200-day moving average of $71.06.
Celsius Holdings的價值高於50日移動均線54.72美元,遠低於200日移動均線71.06美元。
More news about Celsius Holdings.
更多關於Celsius Holdings的新聞。
8. GameStop (GME) – 7.64%
遊戲停止(GME)--7.64%
GameStop Corp. is a retailer of multi-channel consumer electronics and video games in America, Canada, Australia and Europe. It sells pre-owned and new video games platforms, accessories including controllers and virtual reality headsets as well as new and preowned software. The company also offers collectibles that include licensed merchandise. These products are primarily related to video games, TV, and film industries. It operates stores and ecommerce websites under the Micromania, GameStop and EB Games brands. The Zing Pop Culture brand also offers collectibles and Game Informer. This publication, which is both digital and print, features reviews, tips and information about the video gaming industry. The company had 5,509 shops in 14 countries as of February 1, 2020. GSC Holdings Corp. used to be the company's name. GameStop Corp. was established in 1996 in Grapevine Texas.
GameStop Corp.是一家在美國、加拿大、澳大利亞和歐洲銷售多渠道消費電子產品和視頻遊戲的零售商。它銷售二手和新的視頻遊戲平臺,包括控制器和虛擬現實耳機在內的配件,以及新的和二手軟件。該公司還提供包括特許商品在內的收藏品。這些產品主要與視頻遊戲、電視和電影行業有關。它經營着Micromania、GameStop和EB Games品牌的商店和電子商務網站。Zing普普文化品牌還提供收藏品和遊戲告密者。這份出版物既有數字版,也有印刷版,以視頻遊戲行業的評論、提示和信息為特色。截至2020年2月1日,該公司在14個國家擁有5509家門店。GSC Holdings Corp.曾是該公司的名稱。GameStop公司於1996年在德克薩斯州的葡萄園成立。
NYSE ended the session with GameStop rising 7.64% to $152.27 on Tuesday, after two consecutive sessions in a row of losses. NYSE jumped 1.17% to $16,658.90, after two successive sessions in a row of losses, on what was an all-around bullish trend exchanging session today.
週二,在連續兩個交易日下跌後,紐約證交所收盤時GameStop股價上漲7.64%,至152.27美元。紐約證券交易所在連續兩個交易日下跌後,躍升1.17%,至16,658.90美元,今日是全面看漲趨勢交流時段。
Volume
卷
Today's last reported volume for GameStop is 2244120 which is 52.29% below its average volume of 4704230.
今天,GameStop的最新成交量為2244120,比其平均成交量4704230低了52.29%。
GameStop's last close was $92.69, 73.11% under its 52-week high of $344.66.
GameStop最新收盤價為92.69美元,較52周高點344.66美元低73.11%。
News about GameStop today
今日有關遊戲停止的新聞
- GME stock price: gamestop corp sinks as markets pull back to start the week. According to today's article on FXStreet, "It seems the stock split announcement for GameStop has lost its luster for investors. ", "There has been some notable insider buying as recently as the end of March for GameStop shares. "
- GME股價:GameStop公司股價下跌,市場回調,開始本週。根據FXStreet上今天的文章,“GameStop的股票拆分聲明似乎已經失去了投資者的光彩。”“直到3月底,GameStop的股票還出現了一些引人注目的內幕買盤。”
The company's growth estimates for the present quarter is a negative 41.8% and positive 11.1% for the next.
該公司對當前季度的增長預期為負41.8%,對下一季度的增長預期為正11.1%。
GameStop's Revenue
GameStop的收入
Year-on-year quarterly revenue growth grew by 29.1%, now sitting on 5.88B for the twelve trailing months.
季度營收同比增長29.1%,連續12個月達到58.8億歐元。
GameStop's Stock Yearly Top and Bottom Value
GameStop的股票年度最高和最低值
GameStop's stock is valued at $152.27 at 17:32 EST, way below its 52-week high of $344.66 and way higher than its 52-week low of $77.58.
美國東部時間17點32分,GameStop的股價為152.27美元,遠低於52周高點344.66美元,遠高於52周低點77.58美元。
GameStop's Moving Average
GameStop移動平均線
GameStop's value is way above its 50-day moving average of $122.43 and below its 200-day moving average of $162.30.
GameStop的價值遠高於50日移動均線切入位122.43美元,低於200日移動均線切入位162.30美元。
More news about GameStop.
更多有關GameStop的新聞。
9. StoneCo (STNE) – 7.45%
9.StoneCo(STNE)-7.45%
StoneCo Ltd. offers financial technology solutions for clients and integrate partners. It allows customers to transact electronically in Brazil through in-store and online channels. StoneCo Ltd. distributes their solutions through its proprietary Stone Hubs. These hubs offer local sales and services, and technology and solutions for digital merchants via sales personnel, technical vendors and sales staff. It also sells brick-and mortar and digital merchants with the help of a sales team. As of December 31, 2019, the company served approximately 495,100 clients primarily small-and-medium-sized businesses; and 116 integrated partners, such as global payment service providers, digital marketplaces, and integrated software vendors. It was established in 2012 in George Town in the Cayman Islands.
StoneCo Ltd.為客户和整合合作伙伴提供金融技術解決方案。它允許客户在巴西通過店內和在線渠道進行電子交易。StoneCo Ltd.通過其專有的Stone Hub分銷他們的解決方案。這些中心通過銷售人員、技術供應商和銷售人員為數字商家提供本地銷售和服務,以及技術和解決方案。它還在銷售團隊的幫助下銷售實體和數字商家。截至2019年12月31日,該公司為約495,100家客户提供服務,主要是中小企業;以及116家綜合合作伙伴,如全球支付服務提供商、數字市場和綜合軟件供應商。它於2012年在開曼羣島的喬治鎮成立。
NASDAQ ended the session with StoneCo rising 7.45% to $11.10 on Tuesday while NASDAQ rose 2.15% to $13,619.66.
納斯達克週二收盤時上漲7.45%,至11.10美元,納斯達克上漲2.15%,至13,619.66美元。
Volume
卷
Today's last reported volume for StoneCo is 8596570 which is 2.93% below its average volume of 8856130.
今天,StoneCo最新公佈的成交量為8596570台,比8856130台的平均成交量低了2.93%。
StoneCo's last close was $10.33, 89.14% under its 52-week high of $95.12.
StoneCo收盤報10.33美元,較95.12美元的52周高點低89.14%。
StoneCo's Sales
StoneCo的銷售額
StoneCo's sales growth is 40.1% for the current quarter and 51.4% for the next.
StoneCo本季度的銷售額增長為40.1%,下一季度為51.4%。
StoneCo's Revenue
StoneCo的收入
Year-on-year quarterly revenue growth grew by 21.7%, now sitting on 3.33B for the twelve trailing months.
季度營收同比增長21.7%,連續12個月達到33.3億歐元。
StoneCo's Stock Yearly Top and Bottom Value
StoneCo的股票年度最高和最低價值
StoneCo's stock is valued at $11.10 at 17:32 EST, way below its 52-week low of $14.02.
美國東部時間17:32,StoneCo的股價為11.10美元,遠低於其52周低點14.02美元。
StoneCo's Moving Average
斯通科移動平均線
StoneCo's value is way below its 50-day moving average of $27.87 and way below its 200-day moving average of $52.11.
StoneCo的價值遠低於50日移動均線切入位27.87美元,也遠低於200日移動均線切入位52.11美元。
More news about StoneCo.
更多關於StoneCo.的新聞。
10. Generac Holdlings (GNRC) – 7.3%
10.通用控股(GNRC)-7.3%
Generac Holdings Inc. manufactures and sells power generator equipment and energy storage systems. It also designs and produces other products that are suitable for residential, light commercial, industrial, and institutional markets. It offers engine, alternators and transfer switches as well as other components that are fueled by natural gas and liquid propane. The company also offers residential automatic standby generators, with an output range of 6kW-60kW. It also has liquid-cooled generators that have outputs between 22kW and 150kW. Mobile Link is a remote monitoring device for home generators. And industrial diesel generators up to 3250kW. The company also offers portable generators with outputs from 800W up to 17.5kW, engine-driven power washers and water pumps, as well as outdoor power equipment such lawn mowers, trimmers, leaf and log splitters and chipper shredders. Clean energy solutions are available under both the PWRcell or PWRview brand. It also offers light towers and mobile generators as well as flameless heaters. Light-commercial standby generators with outputs of 22kW to 150kW, along with related transfer switches, provide three-phase power to small and medium-sized businesses. Industrial generators have an output range from 10kW to 3250kW, which can be used for emergency back-up in healthcare, telecom, datacom and commercial offices. The company also sells accessories and after-market parts to dealers. Distributed products are sold through independent dealers and industrial distributors as well as national and regional retail partners. Generac Holdings Inc. is located in Waukesha in Wisconsin. It was established in 1959.
Generac Holdings Inc.製造和銷售發電設備和儲能系統。它還設計和生產其他適用於住宅、輕工商業、工業和機構市場的產品。它提供發動機、交流發電機和轉換開關以及其他以天然氣和液態丙烷為燃料的部件。該公司還提供家用自動備用發電機,輸出範圍為6kW-60kW。它還有輸出功率在22千瓦到150千瓦之間的液體冷卻發電機。Mobile Link是一種家庭發電機遠程監控設備。和3250千瓦以下的工業柴油發電機。該公司還提供輸出功率從800瓦到17.5千瓦的便攜式發電機、發動機驅動的電動洗衣機和水泵,以及户外電力設備,如割草機、修剪機、割葉機和原木切割機以及碎紙機。PWRcell或PWRview品牌都提供清潔能源解決方案。它還提供燈塔和移動發電機,以及無焰加熱器。輸出功率為22kW至150kW的輕型商業備用發電機,以及相關的轉換開關,為中小型企業提供三相電力。工業發電機的輸出功率範圍從10kW到3250kW,可用於醫療保健、電信、數據通信和商業辦公室的緊急備用。該公司還向經銷商銷售配件和售後零部件。分銷產品通過獨立經銷商和工業分銷商以及國家和地區零售合作伙伴銷售。Generac Holdings Inc.位於威斯康星州的沃基沙。它成立於1959年。
NYSE ended the session with Generac Holdlings rising 7.3% to $267.46 on Tuesday, after five consecutive sessions in a row of losses. NYSE rose 1.17% to $16,658.90, after two successive sessions in a row of losses, on what was an all-around up trend exchanging session today.
紐約證交所週二收盤上漲7.3%,至267.46美元,此前連續五個交易日下跌。紐約證券交易所在連續兩個交易日下跌後,上漲1.17%,至16,658.90美元,今天是全面上漲的趨勢交流時段。
Volume
卷
Today's last reported volume for Generac Holdlings is 845867 which is 1.76% above its average volume of 831157.
今天Generac Holdling最新公佈的成交量為845867只,比831157只的平均成交量高出1.76%。
Generac Holdlings's last close was $249.27, 52.46% below its 52-week high of $524.31.
忠利控股最後收盤價為249.27美元,較52周高點524.31美元低52.46%。
Generac Holdlings's Sales
Generac Holdling的銷售
Generac Holdlings's sales growth is 37.2% for the present quarter and 35.3% for the next. The company's growth estimates for the ongoing quarter and the next is 14.9% and 39.2%, respectively.
通用控股本季度的銷售額增長為37.2%,下一季度為35.3%。該公司對當前季度和下一季度的增長預期分別為14.9%和39.2%。
Generac Holdlings's Revenue
General Holdling的收入
Year-on-year quarterly revenue growth grew by 69.7%, now sitting on 2.82B for the twelve trailing months.
季度營收同比增長69.7%,連續12個月保持在2.82b的水平。
Stock Price Classification
股票價格分類
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,
根據隨機振盪器,一個有用的超買和超賣狀態指標,
Generac Holdlings's stock is considered to be overbought (>=80).
通用控股的股票被認為是超買(>=80)。
Generac Holdlings's Stock Yearly Top and Bottom Value
通用控股公司股票年度最高和最低價值
Generac Holdlings's stock is valued at $267.46 at 17:32 EST, way below its 52-week high of $524.31 and way higher than its 52-week low of $213.50.
截至美國東部時間17點32分,Generac Holdling的股價為267.46美元,遠低於52周高點524.31美元,遠高於52周低點213.50美元。
Generac Holdlings's Moving Average
一般霍德林斯移動平均線
Generac Holdlings's value is way below its 50-day moving average of $433.60 and way below its 200-day moving average of $389.04.
忠利控股的市值遠低於50日移動均線433.60美元,也遠低於200日移動均線389.04美元。
More news about Generac Holdlings.
更多關於將軍霍德林斯的新聞。
Most Active Losers Today
當今最活躍的失敗者
1. CytRx Corporation (CYTR) – -28.89%
1.CytRx公司(CytRx Corporation)--28.89%
CytRx Corporation is a biopharmaceutical development and research company that focuses on rare and oncology. The company is involved in research and clinical development for novel anticancer drugs. It uses novel linker technology to increase the amount and release of anticancer agents at tumors. Its leading candidates are linker activated drugs release (LADR-7, 8 and 9 respectively, as well as Aldoxorubicin which is a conjugate for the prescribed cytotoxin, doxorubicin. This drug binds to circulating blood albumin and concentrates the drug directly at the tumor site. ACDx is an albumin companion diagnostic tool that identifies patients most likely to be benefited from these potential drug candidates. CytRx Corporation, which was founded in 1985 is located in Los Angeles.
CytRx公司是一家專注於稀有和腫瘤學的生物製藥開發和研究公司。該公司從事新型抗癌藥物的研究和臨牀開發。它使用新的連接物技術來增加腫瘤處抗癌藥物的數量和釋放。它的主要候選藥物是連接子激活的藥物釋放(分別為LADR-7、8和9),以及醛阿黴素,這是規定的細胞毒素阿黴素的結合物。這種藥物與循環血白蛋白結合,並直接在腫瘤部位濃縮藥物。ACDx是一種白蛋白配套診斷工具,可以識別最有可能從這些潛在候選藥物中受益的患者。CytRx公司成立於1985年,位於洛杉磯。
NASDAQ ended the session with CytRx Corporation falling 28.89% to $0.13 on Tuesday while NASDAQ rose 2.15% to $13,619.66.
納斯達克週二收盤時下跌28.89%,至0.13美元,納斯達克上漲2.15%,至13,619.66美元。
Volume
卷
Today's last reported volume for CytRx Corporation is 364002 which is 317.89% above its average volume of 87103.
今天CytRx公司最新報告的成交量為364002台,比其平均成交量87103台高出317.89%。
CytRx Corporation's last close was $0.13, 97.28% below its 52-week high of $4.70.
CytRx Corporation最新收盤報0.13美元,較其52周高點4.70美元低97.28%。
Stock Price Classification
股票價格分類
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,
根據隨機振盪器,一個有用的超買和超賣狀態指標,
CytRx Corporation's stock is considered to be overbought (>=80).
CytRx公司的股票被認為是超買(>=80)。
CytRx Corporation's Stock Yearly Top and Bottom Value
CytRx公司股票年度最高和最低價值
CytRx Corporation's stock is valued at $0.13 at 17:32 EST, way below its 52-week high of $4.70 and above its 52-week low of $0.13.
美國東部時間17:32,CytRx Corporation的股價為0.13美元,遠低於4.70美元的52周高點,高於0.13美元的52周低點。
CytRx Corporation's Moving Average
CytRx公司的移動平均線
CytRx Corporation's worth is way under its 50-day moving average of $0.39 and way below its 200-day moving average of $0.57.
CytRx公司的市值遠低於50日移動均線0.39美元,也遠低於200日移動均線0.57美元。
More news about CytRx Corporation.
更多關於CytRx公司的新聞。
2. Esperion Therapeutics (ESPR) – -14.6%
2.Esperion Treateutics(ESPR)--14.6%
Esperion Therapeutics, Inc. is a pharmaceutical company that develops and markets medicines to treat patients suffering from high levels of low-density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. Daiichi Sankyo Europe GmbH and Serometrix have entered into a collaboration and license agreement. This allows the company to in-license their oral small-molecule PCSK9 inhibitor programs. Esperion Therapeutics, Inc., was founded in 2008. It is located in Ann Arbor, Michigan.
Esperion Treateutics,Inc.是一家制藥公司,開發和銷售治療低密度脂蛋白膽固醇水平高的患者的藥物。它的主要候選產品是用於治療動脈粥樣硬化性心血管疾病或雜合性家族性高膽固醇血癥患者的NEXLETOL(苯培多酸)和NEXLIZET(苯培多酸和依折麥布)片劑。Daiichi Sankyo Europe GmbH和Serometrix已達成合作和許可協議。這使得該公司能夠授權他們的口服小分子PCSK9抑制劑計劃。Esperion Treateutics,Inc.成立於2008年。它位於密歇根州的安娜堡。
NASDAQ ended the session with Esperion Therapeutics sliding 14.6% to $5.03 on Tuesday while NASDAQ rose 2.15% to $13,619.66.
週二,納斯達克收盤時下跌14.6%,至5.03美元,納斯達克上漲2.15%,至13619.66美元。
Volume
卷
Today's last reported volume for Esperion Therapeutics is 2759780 which is 116.33% above its average volume of 1275710.
今天,Esperion Treateutics的最新報告數量為2759780,比其平均數量1275710高出116.33%。
Esperion Therapeutics's last close was $5.03, 82.52% below its 52-week high of $28.78.
Esperion Treateutics的最後收盤價為5.03美元,較其52周高點28.78美元低82.52%。
Esperion Therapeutics's Sales
Esperion Treateutics的銷售額
Esperion Therapeutics's sales growth is 49.1% for the present quarter and 122.6% for the next. The company's growth estimates for the ongoing quarter and the next is 31.9% and 66.9%, respectively.
Esperion治療公司本季度的銷售額增長率為49.1%,下一季度為122.6%。該公司對當前季度和下一季度的增長預期分別為31.9%和66.9%。
Esperion Therapeutics's Revenue
Esperion Treateutics的收入
Year-on-year quarterly revenue growth grew by 275.9%, now sitting on 72.68M for the twelve trailing months.
與去年同期相比,季度收入增長了275.9%,連續12個月達到7268萬。
Esperion Therapeutics's Stock Yearly Top and Bottom Value
Esperion Treateutics的股票年度最高和最低值
Esperion Therapeutics's stock is valued at $5.03 at 17:33 EST, way under its 52-week high of $28.78 and way above its 52-week low of $3.28.
截至美國東部時間17:33,Esperion Treateutics的股價為5.03美元,遠低於28.78美元的52周高點,遠高於3.28美元的52周低點。
Esperion Therapeutics's Moving Average
Esperion Treateutics的移動平均值
Esperion Therapeutics's value is higher than its 50-day moving average of $4.63 and way below its 200-day moving average of $8.75.
Esperion Treateutics的價值高於其50日移動均線4.63美元,遠低於其200日移動均線8.75美元。
More news about Esperion Therapeutics.
更多關於Esperion Treateutics的新聞。
3. Evolving Systems (EVOL) – -11.72%
3.演進系統(EVOL)--11.72%
Evolving Systems, Inc. offers real-time digital engagement services and solutions to both the mobile carrier market and the consumer financial markets internationally. It offers activation and acquisition solutions. These include Smart Dealer which enables SIM card retailers to sell SIM cards. Dynamic SIM Allocation is a SIM/eSIM activation tool. The company's activation and acquisition solutions include Tertio Service activation, which is used to activate new subscribers or add new services to existing subscribers; and Number Inventory and Management Solution. This solution automates the management of operators' telephone numbers and other communications identifiers. The company also offers value management and customer analytics solutions such as the Profiling Engine (a rules-driven flexible aggregater that supports dynamic and static profiling of subscribers); Campaign Engine which is used for delivering marketing offers and campaigns to subscribers; Campaign Workflow, Journey Manager and Campaign Workflow, which offer predefined templates to support specific digital marketing strategies; Real-time Predictions and Machine Learning Module, which allows revenue, usage and churn predictions. It also offers a Social Media Integration Solution that allows carriers to increase their engagement with subscribers. The company also offers loyalty and customer retention solutions to reduce churn and increase customer lifetimes. The company also offers managed IT and marketing services, as well as customer value management and solutions. It was established in Englewood in Colorado in 1985.
發展系統公司向移動運營商市場和國際消費金融市場提供實時數字參與服務和解決方案。它提供激活和獲取解決方案。其中包括Smart Dealer,它使SIM卡零售商能夠銷售SIM卡。動態SIM卡分配是一個SIM卡/eSIM卡激活工具。該公司的激活和收購解決方案包括Tertio服務激活,用於激活新用户或向現有用户添加新服務;以及號碼清點和管理解決方案。該解決方案可自動管理運營商的電話號碼和其他通信標識。該公司還提供價值管理和客户分析解決方案,如Profile Engine(一個支持動態和靜態用户概況的規則驅動的靈活聚合器);Campaign Engine,用於向訂户提供營銷優惠和活動;Campaign Workflow、Journey Manager和Campaign Workflow,它提供預定義的模板,以支持特定的數字營銷戰略;實時預測和機器學習模塊,它允許收入、使用和流失預測。它還提供社交媒體集成解決方案,允許運營商增加與訂户的接觸。該公司還提供忠誠度和客户保留率解決方案,以減少流失和延長客户生命週期。該公司還提供管理的IT和營銷服務,以及客户價值管理和解決方案。它於1985年在科羅拉多州的恩格爾伍德成立。
NASDAQ ended the session with Evolving Systems falling 11.72% to $1.28 on Tuesday while NASDAQ rose 2.15% to $13,619.66.
納斯達克週二收盤時下跌11.72%,至1.28美元,納斯達克上漲2.15%,至13,619.66美元。
Volume
卷
Today's last reported volume for Evolving Systems is 362059 which is 266.28% above its average volume of 98847.
今天最新報告的演進系統成交量為362059,比98847的平均成交量高出266.28%。
Evolving Systems's last close was $1.28, 59.49% below its 52-week high of $3.16.
Evolving Systems的最後收盤價為1.28美元,較3.16美元的52周高點低59.49%。
Evolving Systems's Revenue
演進系統公司的收入
Year-on-year quarterly revenue growth grew by 3%, now sitting on 27.39M for the twelve trailing months.
與去年同期相比,季度收入增長了3%,連續12個月增長2739萬。
Evolving Systems's Stock Yearly Top and Bottom Value
演進系統公司股票年度最高和最低價值
Evolving Systems's stock is valued at $1.28 at 17:33 EST, way under its 52-week high of $3.16 and higher than its 52-week low of $1.27.
美國東部時間17點33分,Evolving Systems的股價為1.28美元,遠低於3.16美元的52周高點,也高於1.27美元的52周低點。
Evolving Systems's Moving Average
演進系統的移動平均數
Evolving Systems's worth is way under its 50-day moving average of $1.83 and way under its 200-day moving average of $2.17.
Evolving Systems的市值遠低於1.83美元的50日移動均線和2.17美元的200日移動均線。
More news about Evolving Systems.
更多關於進化系統的新聞。
4. FalconStor Software (FALC) – -9.57%
4.FalconStor軟件(Falc)--9.57%
FalconStor Software, Inc., is a storage software firm that develops, sells, and supports data migration, business continuity, disaster relief, optimized backup, duplication, and any other maintenance, implementation, or engineering services. FalconStor Virtual Tape Library is a program that replaces legacy tape libraries. It also offers FalconStor Continuous data Protector, which allows for instant recovery, data availability and reliability, as well as FalconStor Storage Server, for virtualizing data and ensuring business continuity across heterogeneous environments. FalconStor RecoverTrac Disaster Recovery Technology streamlines implementation, testing and execution of disaster recovery procedures. FalconStor MicroScanTM Technology reduces data transfer during replication, by eliminating inefficiencies and errors at the file system and application layer. It sells products via authorized partners, value-added distributors and solution providers. FalconStor Software, Inc., was founded in 1994. It is located in Austin, Texas.
FalconStor Software,Inc.是一家存儲軟件公司,開發、銷售和支持數據遷移、業務連續性、災難救援、優化備份、複製以及任何其他維護、實施或工程服務。FalconStor虛擬磁帶庫是一個取代傳統磁帶庫的程序。它還提供了可實現即時恢復、數據可用性和可靠性的FalconStor連續數據保護器,以及用於虛擬化數據和確保跨異類環境的業務連續性的FalconStor存儲服務器。FalconStor RecoverTrac災難恢復技術簡化了災難恢復程序的實施、測試和執行。FalconStor MicroScanTM技術通過消除文件系統和應用程序層的低效和錯誤,減少了複製過程中的數據傳輸。它通過授權合作伙伴、增值分銷商和解決方案提供商銷售產品。FalconStor軟件公司成立於1994年。它位於德克薩斯州的奧斯汀。
NASDAQ ended the session with FalconStor Software dropping 9.57% to $1.04 on Tuesday while NASDAQ rose 2.15% to $13,619.66.
週二,納斯達克收盤時下跌9.57%,至1.04美元,納斯達克上漲2.15%,至13,619.66美元。
Volume
卷
Today's last reported volume for FalconStor Software is 326 which is 89.61% below its average volume of 3139.
今天,FalconStor Software的最新報告成交量為326台,比3139台的平均成交量低89.61%。
FalconStor Software's last close was $1.04, 82.67% below its 52-week high of $6.00.
FalconStor Software最新收盤報1.04美元,較其52周高點6.00美元低82.67%。
FalconStor Software's Revenue
FalconStor軟件的收入
Year-on-year quarterly revenue growth declined by 26%, now sitting on 14.02M for the twelve trailing months.
與去年同期相比,季度收入增長下降了26%,連續12個月增長1402萬。
FalconStor Software's Stock Yearly Top and Bottom Value
FalconStor軟件的股票年度最高和最低價值
FalconStor Software's stock is valued at $1.04 at 17:33 EST, way below its 52-week high of $6.00 and way higher than its 52-week low of $0.55.
美國東部時間17時33分,FalconStor Software的股價為1.04美元,遠低於6.00美元的52周高點,遠高於0.55美元的52周低點。
FalconStor Software's Moving Average
FalconStor軟件的移動平均線
FalconStor Software's worth is way under its 50-day moving average of $1.67 and way under its 200-day moving average of $2.87.
FalconStor Software的價值遠低於1.67美元的50日移動均線,也遠低於2.87美元的200日移動均線。
More news about FalconStor Software.
更多關於FalconStor軟件的新聞。
5. DURECT Corporation (DRRX) – -7.64%
5.杜邦公司(DURECT Corporation)--7.64%
DURECT Corporation is a biopharmaceutical firm that develops drugs based on the company's epigenetic regulators and pharmaceutical programs. ALZET is a product line of ALZET osmotic pumps, accessories, and equipment that are used in research on mice, rats and other laboratory animals. DUR-928 is an orally bioavailable, endogenous small molecule. It has completed Phase Ib clinical trials to treat nonalcoholic steatohepatitis patients. The company also offers POSIMIR which is a pain relief product that delivers bupivacaine for up to 7 days in adults. The company markets its ALZET products through direct sales in the United States as well as via a network distributors in Japan and Europe. It has agreements and strategic collaboration with Indivior UK Ltd., Virginia Commonwealth University Intellectual Property Foundation, Santen Pharmaceutical Co., Ltd., Sandoz AG, and Gilead Sciences, Inc. DURECT Corporation was established in 1998. The corporation is located in Cupertino, California.
DURECT公司是一家生物製藥公司,根據該公司的表觀遺傳調節器和製藥計劃開發藥物。ALZET是ALZET滲透泵、附件和設備的產品線,用於小鼠、大鼠和其他實驗動物的研究。DUR-928是一種口服生物利用型內源性小分子藥物。它已經完成了治療非酒精性脂肪性肝炎患者的Ib期臨牀試驗。該公司還提供POSIMIR,這是一種止痛產品,可以為成年人提供長達7天的布比卡因。該公司通過在美國的直銷以及在日本和歐洲的網絡分銷商來營銷其ALZET產品。它與InDior UK Ltd.、弗吉尼亞聯邦大學知識產權基金會、Santen製藥有限公司、Sandoz AG和Gilead Science,Inc.簽訂了協議並進行了戰略合作。DURECT公司成立於1998年。該公司位於加利福尼亞州庫比蒂諾。
NASDAQ ended the session with DURECT Corporation sliding 7.64% to $0.44 on Tuesday, following the last session's downward trend. NASDAQ rose 2.15% to $13,619.66, after two successive sessions in a row of losses, on what was an all-around positive trend exchanging session today.
納斯達克週二收盤時下跌7.64%,至0.44美元,延續上一交易日的下跌趨勢。納斯達克在連續兩個交易日下跌後上漲2.15%,至13,619.66美元,今日是全面上漲的趨勢交流時段。
Volume
卷
Today's last reported volume for DURECT Corporation is 1091780 which is 66.5% above its average volume of 655713.
今天DURECT公司最新報告的成交量為1091780,比其平均成交量655713高出66.5%。
DURECT Corporation's last close was $0.44, 77.2% below its 52-week high of $1.93.
DURECT Corporation最新收盤報0.44美元,較52周高點1.93美元低77.2%。
DURECT Corporation's Sales
DURECT公司的銷售
DURECT Corporation's sales growth is a negative 21.9% for the ongoing quarter and 10.7% for the next.
DURECT公司本季度的銷售額增長為負21.9%,下一季度為10.7%。
DURECT Corporation's Revenue
DURECT公司的收入
Year-on-year quarterly revenue growth grew by 230.6%, now sitting on 13.98M for the twelve trailing months.
與去年同期相比,季度收入增長了230.6%,連續12個月增長1398萬。
DURECT Corporation's Stock Yearly Top and Bottom Value
DURECT公司股票年度最高和最低價值
DURECT Corporation's stock is valued at $0.44 at 17:33 EST, below its 52-week low of $0.44.
在美國東部時間17:33,DURECT Corporation的股票估值為0.44美元,低於52周低點0.44美元。
DURECT Corporation's Moving Average
DURECT公司移動平均線
DURECT Corporation's value is way under its 50-day moving average of $0.62 and way under its 200-day moving average of $1.02.
DURECT Corporation的市值遠低於50日移動均線0.62美元,也遠低於200日移動均線1.02美元。
More news about DURECT Corporation.
更多關於DURECT公司的新聞。
6. First Majestic Silver (AG) – -6.41%
6.第一銀牌(AG)--6.41%
First Majestic Silver Corp. is engaged in exploration, development and production of mineral properties, with a particular focus on Mexico. San Dimas Silver/Gold Mine is 100% owned by the company. It consists of 119 concessions that cover an area 71,868 ha in Durango. Santa Elena Silver/Gold Mine covers an area 57,656 Ha in Sonora. La Encantada Silver Mine has 22 concessions and an area 4,076 ha in Coahuila. Surface land ownership totals 1,343 He. The company also has an interest in the Springpole gold-silver project that covers approximately 41,943 ha in Ontario, Canada. The original name of the company was First Majestic Resource Corp., but it changed its name in November 2006 to First Majestic Silver Corp. First Majestic Silver Corp. is an American corporation that was founded in 1979. Its headquarters are located in Vancouver, Canada.
First Majestic Silver Corp.從事礦產資源的勘探、開發和生產,特別關注墨西哥。聖迪馬斯銀金礦由該公司100%擁有。它由119個特許權組成,覆蓋杜蘭戈71,868公頃的面積。聖埃琳娜銀金礦佔地57,656公頃,位於索諾拉。La Encantada銀礦在科阿韋拉擁有22個特許權和4076公頃的面積。地表土地所有權總額為1,343公頃。該公司還在加拿大安大略省佔地約41,943公頃的Springole金銀項目中擁有權益。該公司最初的名稱是First Majestic Resource Corp.,但在2006年11月更名為First Majestic Silver Corp.。First Majestic Silver Corp.是一家成立於1979年的美國公司。其總部設在加拿大温哥華。
NYSE ended the session with First Majestic Silver sliding 6.41% to $13.00 on Tuesday while NYSE rose 1.17% to $16,658.90.
紐約證交所週二收盤時First Majestic Silver下跌6.41%,至13.00美元,紐約證交所上漲1.17%,至16,658.90美元。
Volume
卷
Today's last reported volume for First Majestic Silver is 8102550 which is 30.99% above its average volume of 6185230.
今天公佈的First Majestic Silver成交量為8102550枚,較6185230枚的平均成交量高出30.99%。
First Majestic Silver's last close was $13.39, 29.27% below its 52-week high of $18.93.
First Majestic Silver最新收盤報13.39美元,較52周高點18.93美元低29.27%。
First Majestic Silver's Revenue
First Majestic Silver的收入
Year-on-year quarterly revenue growth declined by 1%, now sitting on 496.32M for the twelve trailing months.
與去年同期相比,季度收入增長下降了1%,連續12個月保持在4.9632億美元的水平。
First Majestic Silver's Stock Yearly Top and Bottom Value
第一大白銀股票年度最高和最低價值
First Majestic Silver's stock is valued at $13.00 at 17:33 EST, way under its 52-week high of $18.93 and way above its 52-week low of $9.29.
在美國東部時間17:33,First Majestic Silver的股價為13.00美元,遠低於18.93美元的52周高點,遠高於9.29美元的52周低點。
First Majestic Silver's Moving Average
第一個馬傑斯蒂克銀牌移動平均線
First Majestic Silver's worth is higher than its 50-day moving average of $11.97 and higher than its 200-day moving average of $12.40.
First Majestic Silver的價值高於其50日移動均線11.97美元,也高於其200日移動均線12.40美元。
More news about First Majestic Silver.
更多關於First Majestic Silver的消息。
7. Fate Therapeutics (FATE) – -6.06%
7.Fate Treeutics(Fate)--6.06%
Fate Therapeutics, Inc. is a biopharmaceutical firm in clinical stage. It develops programmed cell immunotherapies for immune disorders and cancer. It is currently developing NK-and T-cell immuno-oncology programmes for AML, B-cell Lymphoma, and advanced Solid Tumors. FT516 to treat AML, B-cell and multiple myeloma. FT538 to manage multiple myeloma. FT576 and FT538 are for multiple myeloma. FT819 and solid cancers. FT536 and FT500 to deal with advanced solid tumours. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc., was founded in 2007. It is located in San Diego, California.
Fate治療公司是一家處於臨牀階段的生物製藥公司。它開發針對免疫紊亂和癌症的程序化細胞免疫療法。它目前正在為AML、B細胞淋巴瘤和晚期實體腫瘤開發NK和T細胞免疫腫瘤學計劃。FT516用於治療AML、B細胞和多發性骨髓瘤。FT538用於管理多發性骨髓瘤。FT576和FT538是針對多發性骨髓瘤的。FT819和實體癌。FT536和FT500用於治療晚期實體腫瘤。該公司與小野製藥有限公司就兩種現成的iPSC衍生CAR T細胞候選產品的開發和商業化達成了合作和期權協議;與Juno治療公司有戰略研究合作和許可協議,以篩選和確定增強轉基因T細胞免疫療法的治療性能的小分子調節劑;與Janssen Biotech,Inc.合作和期權協議成立於2007年。它位於加利福尼亞州的聖地亞哥。
NASDAQ ended the session with Fate Therapeutics falling 6.06% to $35.48 on Tuesday while NASDAQ jumped 2.15% to $13,619.66.
週二,納斯達克收盤時下跌6.06%,至35.48美元,納斯達克上漲2.15%,至13,619.66美元。
Volume
卷
Today's last reported volume for Fate Therapeutics is 790201 which is 40.28% below its average volume of 1323370.
今天,Fate Treateutics最新報告的成交量為790201份,比其平均成交量1323370份低40.28%。
Fate Therapeutics's last close was $35.48, 63.58% under its 52-week high of $97.43.
Fate Treateutics收盤報35.48美元,較97.43美元的52周高點低63.58%。
Fate Therapeutics's Sales
Fate Treateutics的銷售
Fate Therapeutics's sales growth is a negative 16% for the ongoing quarter and 62.8% for the next. The company's growth estimates for the present quarter and the next is a negative 58.3% and a negative 37.9%, respectively.
Fate治療公司本季度的銷售額增長為負16%,下一季度為62.8%。該公司對當前季度和下一季度的增長預期分別為負58.3%和負37.9%。
Fate Therapeutics's Revenue
命運治療公司的收入
Year-on-year quarterly revenue growth grew by 7.4%, now sitting on 55.85M for the twelve trailing months.
與去年同期相比,季度收入增長了7.4%,連續12個月增長5585萬。
Fate Therapeutics's Stock Yearly Top and Bottom Value
Fate Treateutics股票年度最高和最低值
Fate Therapeutics's stock is valued at $35.48 at 17:33 EST, way under its 52-week high of $97.43 and way above its 52-week low of $29.40.
在美國東部時間17:33,命運治療公司的股價為35.48美元,遠低於97.43美元的52周高點,遠高於29.40美元的52周低點。
Fate Therapeutics's Moving Average
命運治療公司的移動平均線
Fate Therapeutics's value is under its 50-day moving average of $36.56 and way under its 200-day moving average of $56.91.
命運治療公司的價值低於其50日移動均線36.56美元,也遠低於其200日移動均線56.91美元。
More news about Fate Therapeutics.
更多關於命運治療公司的新聞。
8. Epizyme (EPZM) – -6.03%
8.伊匹西姆(EPZM)--6.03%
Epizyme, Inc., is a biopharmaceutical firm in commercial stage. It develops, commercializes, and markets novel epigenetic drugs for cancer patients and other diseases throughout the United States. Tazemetostat is available for treatment of epithelioid tumors in adults or children. Tazemetostat is also developed in conjunction with Rituximab for patients with follicular Lymphoma. It also offers R-CHOP in front line patients with high-risk diffuse large B cell lymphoma (DLBCL) and PARP inhibitor to patients with solid platinum-resistant tumors such as small-cell lung carcinoma, triple-negative breast and ovarian cancer. It also develops Tazemetostat for patients with castration resistant prostate cancer and children and adults with INI1 negative tumors. The company also develops pinometostat to treat acute myeloid and acute lymphoblastic lesions; PRMT5 inhibitors for solid tumors patients; and PRMT1 inhibitor. Epizyme, Inc. is a partner of Genentech Inc., Glaxo Group Limited, Roche Molecular Systems, Inc., Lymphoma Academic Resource Organization, Eisai Co. Ltd., and HUTCHMED China Limited. It was founded in 2007, and has its headquarters in Cambridge, Massachusetts.
艾匹克姆公司是一家處於商業階段的生物製藥公司。該公司在全美為癌症患者和其他疾病開發、商業化和銷售新型表觀遺傳藥物。他莫司坦可用於治療成人或兒童的上皮樣腫瘤。他莫司坦也與利妥昔單抗聯合開發,用於濾泡性淋巴瘤患者。它還為高危瀰漫性大B細胞淋巴瘤(DLBCL)一線患者提供R-CHOP,併為小細胞肺癌、三陰性乳腺癌和卵巢癌等實體鉑耐藥腫瘤患者提供PARP抑制劑。它還為耐去勢前列腺癌患者以及INI1陰性腫瘤的兒童和成人開發他西司坦。該公司還開發了用於治療急性髓系和急性淋巴母細胞病變的Pinetostat;用於實體腫瘤患者的PRMT5抑制劑;以及PRMT1抑制劑。艾匹克姆公司是基因泰克公司、葛蘭素史克集團有限公司、羅氏分子系統公司、淋巴瘤學術資源組織、衞材株式會社和和黃醫藥有限公司的合作伙伴。它成立於2007年,總部設在馬薩諸塞州劍橋市。
NASDAQ ended the session with Epizyme falling 6.03% to $0.72 on Tuesday while NASDAQ rose 2.15% to $13,619.66.
納斯達克週二收盤時下跌6.03%,至0.72美元,納斯達克上漲2.15%,至13,619.66美元。
Volume
卷
Today's last reported volume for Epizyme is 1917660 which is 40.86% below its average volume of 3242790.
今天報告的最新成交量為1917660只,比3242790只的平均成交量低了40.86%。
Epizyme's last close was $0.72, 92.7% under its 52-week high of $9.86.
EPizyme最新收盤報0.72美元,較其52周高點9.86美元低92.7%。
Epizyme's Sales
伊皮奇姆的銷售額
Epizyme's sales growth is a negative 1.4% for the current quarter and a decline by 3.4% for the next. The company's growth estimates for the present quarter and the next is 16.9% and 24.6%, respectively.
該公司本季度的銷售額增長為負1.4%,下一季度將下降3.4%。該公司對當前季度和下一季度的增長預估分別為16.9%和24.6%。
Epizyme's Revenue
埃皮奇姆的收入
Year-on-year quarterly revenue growth grew by 38.3%, now sitting on 37.43M for the twelve trailing months.
季度營收同比增長38.3%,連續12個月增長3743萬。
Epizyme's Stock Yearly Top and Bottom Value
艾匹克姆的股票年度最高和最低價值
Epizyme's stock is valued at $0.72 at 17:33 EST, way below its 52-week high of $9.86 and higher than its 52-week low of $0.70.
美國東部時間17:33,EPizyme的股價為0.72美元,遠低於其52周高點9.86美元,高於其52周低點0.70美元。
Epizyme's Moving Average
埃皮切姆移動平均線
Epizyme's worth is way below its 50-day moving average of $1.33 and way below its 200-day moving average of $3.72.
EPizyme的價值遠低於50日移動均線切入位1.33美元,也遠低於200日移動均線切入位3.72美元。
More news about Epizyme.
更多關於艾匹克梅的新聞。
9. TherapeuticsMD (TXMD) – -5.74%
9.治療藥物(TXMD)--5.74%
TherapeuticsMD, Inc. is a United States women's health company. The company provides IMVEXXY, a treatment for moderate-to severe dyspareunia, and BIJUVA which is a bioidentical hormonal therapy combination of 17AY-estradiol, progesterone, for moderate to severe vasomotor symptoms. TX-015HR is a transdermal patch candidate that contains progesterone and estradiol. TX-009HR is the company's clinical product. It contains an oral progesterone/estradiol formula. The company also produces and distributes generic and branded prescription prenatal vitamins under the vitaTrue and vitaMedMD brands. It sells prescription hormone therapy drugs and prenatal vitamins to both wholesale and retail pharmacie distributors. TherapeuticsMD, Inc., is located in Boca Raton, Florida.
TreateuticsMD,Inc.是一家美國婦女保健公司。該公司提供IMVEXXY和BIJUVA,IMVEXXY是一種治療中到重度性交困難的藥物,BIJUVA是一種生物相同的激素療法,由17AY-雌二醇和孕酮組合而成,用於治療中到重度的血管舒縮症狀。TX-015HR是一種含孕酮和雌二醇的透皮貼劑候選藥物。TX-009HR是該公司的臨牀產品。它含有口服黃體酮/雌二醇配方。該公司還以vitaTrue和vitaMedMD品牌生產和分銷非專利和品牌處方產前維生素。它向批發和零售藥店分銷商銷售處方激素治療藥物和產前維生素。TreateuticsMD,Inc.位於佛羅裏達州博卡拉頓。
NASDAQ ended the session with TherapeuticsMD falling 5.74% to $0.27 on Tuesday while NASDAQ jumped 2.15% to $13,619.66.
納斯達克週二收盤時下跌5.74%,至0.27美元,納斯達克上漲2.15%,至13,619.66美元。
Volume
卷
Today's last reported volume for TherapeuticsMD is 5149540 which is 26.89% below its average volume of 7043920.
今天最新報告的TreateuticsMD成交量為5149540份,比其平均成交量7043920份低26.89%。
TherapeuticsMD's last close was $0.28, 89.67% under its 52-week high of $2.75.
TreateuticsMD的最後收盤價為0.28美元,較2.75美元的52周高點低89.67%。
TherapeuticsMD's Sales
TreeuticsMD的銷售
TherapeuticsMD's sales growth is 33.7% for the ongoing quarter and 29.3% for the next. The company's growth estimates for the present quarter and the next is 16.7% and 40%, respectively.
TreateuticsMD的銷售額在本季度增長了33.7%,下一季度增長了29.3%。該公司對當前季度和下一季度的增長預估分別為16.7%和40%。
TherapeuticsMD's Revenue
治療公司MD的收入
Year-on-year quarterly revenue growth grew by 114.9%, now sitting on 84.79M for the twelve trailing months.
季度營收同比增長114.9%,連續12個月增長至8479萬歐元。
Stock Price Classification
股票價格分類
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,
根據隨機振盪器,一個有用的超買和超賣狀態指標,
TherapeuticsMD's stock is considered to be overbought (>=80).
TreateuticsMD的股票被認為是超買(>=80)。
TherapeuticsMD's Stock Yearly Top and Bottom Value
TreateuticsMD的年度庫存最高和最低值
TherapeuticsMD's stock is valued at $0.27 at 17:34 EST, way below its 52-week low of $0.37.
在美國東部時間17:34,TreateuticsMD的股價為0.27美元,遠低於0.37美元的52周低點。
TherapeuticsMD's Moving Average
治療學MD的移動平均數
TherapeuticsMD's value is way below its 50-day moving average of $0.66 and way under its 200-day moving average of $1.00.
TreateuticsMD的價值遠低於其50天移動均線0.66美元,也遠低於其200天移動均線1.00美元。
More news about TherapeuticsMD.
更多有關TreateuticsMD的新聞。
10. Enanta Pharmaceuticals (ENTA) – -5.05%
10.埃南塔製藥(Enta)--5.05%
Enanta Pharmaceuticals, Inc. is a biotechnology firm that develops small-molecule drugs to treat viral infections. The company's main research and development diseases targets are respiratory syncytial, non-alcoholic, steatohepatitis and SARS-CoV-2. It also has human metapneumovirus and hepatitis B viruses. Glecaprevir is available for chronic hepatitis C, and HCV. It's also offered under MAVYRET or MAVIRET. Enanta Pharmaceuticals, Inc. and Abbott Laboratories have a collaboration development and licensing agreement to develop and commercialize HCV NS3 inhibitor compounds and NS3/4A protease inhibitor compounds. This includes paritaprevir, glecaprevir, and glecaprevir in the treatment of chronic hepatitis C. Watertown, Massachusetts is the headquarters of Enanta Pharmaceuticals Inc. It was established in 1995.
Enanta製藥公司是一家生物技術公司,開發治療病毒感染的小分子藥物。該公司主要研發的疾病目標是呼吸道合胞、非酒精性、脂肪性肝炎和SARS-CoV-2。它還有人類偏肺病毒和乙肝病毒。格來昔韋可用於慢性丙型肝炎和丙型肝炎。它也以MAVYRET或MAVIRET的形式提供。埃南塔製藥公司和雅培公司有一項合作開發和許可協議,以開發和商業化丙型肝炎病毒NS3抑制劑化合物和NS3/4A蛋白酶抑制劑化合物。這包括治療慢性丙型肝炎的paritaprevir、glecaprevir和glecapvir。馬薩諸塞州沃特敦是Enanta製藥公司的總部,成立於1995年。
NASDAQ ended the session with Enanta Pharmaceuticals sliding 5.05% to $70.50 on Tuesday, after two successive sessions in a row of losses. NASDAQ jumped 2.15% to $13,619.66, after two consecutive sessions in a row of losses, on what was an all-around bullish trend trading session today.
週二,納斯達克在連續兩個交易日下跌後,收盤時下跌5.05%,至每股70.50美元。納斯達克在連續兩個交易日下跌後躍升2.15%,至13,619.66美元,今日是全面看漲的交易日。
Volume
卷
Today's last reported volume for Enanta Pharmaceuticals is 185820 which is 14.44% below its average volume of 217201.
今天公佈的Enanta PharmPharmticals最新成交量為185820只,較217201只的平均成交量低14.44%。
Enanta Pharmaceuticals's last close was $70.50, 30.88% under its 52-week high of $102.00.
Enanta PharmPharmticals最新收盤報70.50美元,較52周高點102.00美元低30.88%。
The company's growth estimates for the current quarter and the next is a negative 31.2% and a negative 21.8%, respectively.
該公司對當前季度和下一季度的增長預期分別為負31.2%和負21.8%。
Enanta Pharmaceuticals's Revenue
Enanta製藥公司的收入
Year-on-year quarterly revenue growth declined by 12.9%, now sitting on 92.98M for the twelve trailing months.
季度營收同比增長12.9%,連續12個月保持在9298萬美元。
Enanta Pharmaceuticals's Stock Yearly Top and Bottom Value
Enanta製藥公司股票年度最高和最低值
Enanta Pharmaceuticals's stock is valued at $70.50 at 17:34 EST, way under its 52-week high of $102.00 and way higher than its 52-week low of $40.37.
在美國東部時間17點34分,Enanta PharmPharmticals的股價為70.5美元,遠低於52周高點102.00美元,也遠高於52周低點40.37美元。
Enanta Pharmaceuticals's Moving Average
Enanta製藥公司的移動平均線
Enanta Pharmaceuticals's value is higher than its 50-day moving average of $68.12 and higher than its 200-day moving average of $64.95.
Enanta PharmPharmticals的價值高於50日移動均線切入位68.12美元,也高於200日移動均線切入位64.95美元。
More news about Enanta Pharmaceuticals.
更多關於Enanta製藥的新聞。
Stay up to date with our winners and losers daily report
隨時關注我們的贏家和輸家每日報告